Incidence of and risk for osteonecrosis of the jaw in Korean osteoporosis patients treated with bisphosphonates: A nationwide cohort-study

被引:20
|
作者
Kim, Se Hwa [1 ]
Lee, Young-Kyun [2 ]
Kim, Tae-Young [3 ]
Ha, Yong-Chan [4 ]
Jang, Sunmee [5 ,6 ]
Kim, Ha Young [7 ,8 ]
机构
[1] Catholic Kwandong Univ, Int St Marys Hosp, Dept Internal Med, Coll Med, Incheon, South Korea
[2] Seoul Natl Univ, Bundang Hosp, Dept Orthopaed Surg, Seongnam, South Korea
[3] Konkuk Univ, Sch Med, Dept Orthopaed Surg, Seoul, South Korea
[4] Chung Ang Univ, Dept Orthopaed Surg, Coll Med, Seoul, South Korea
[5] Gachon Univ, Coll Pharm, Incheon, South Korea
[6] Gachon Univ, Gachon Inst Pharmaceut Sci, Incheon, South Korea
[7] Wonkwang Univ, Sanbon Hosp, Dept Internal Med, Coll Med, Gunpo, South Korea
[8] Univ Ulsan, Gangneung Asan Hosp, Dept Internal Med, Coll Med, Kangnung, South Korea
关键词
Bisphosphonates; Osteonecrosis of the jaw; Osteoporosis; Periodontal disease; SUPPRESSED BONE TURNOVER; ZOLEDRONIC ACID; POSTMENOPAUSAL OSTEOPOROSIS; RHEUMATOID-ARTHRITIS; ALENDRONATE; FRACTURES; WOMEN; ASSOCIATION; PREVALENCE;
D O I
10.1016/j.bone.2020.115650
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: To estimate the incidence of osteonecrosis of the jaw (ONJ) in patients treated with bisphosphonates (BPs) and to identify clinical risk factors that increase the risk for ONJ in Korean osteoporosis patients. Methods: We used data acquired from the Korean National Health Insurance Service. Among 2,140,149 participants with osteoporosis in 2012, we selected 164,926 new BP users and 164,926 ageand sex-matched control subjects. The control group included only patients with no prescriptions for BPs between January 1, 2011, and December 31, 2016. Participants were followed for 4 years. Results: Over the 4-year follow-up period, the cumulative incidence rates of ONJ were 20.9 and 6.9 per 100,000 person-years in the BP and control groups, respectively. The BP group had an increased risk for ONJ compared to the control group after adjusting for multiple variables (hazard ratio [HR] 3.72, 95% CI 2.70-5.11). Advanced age (>= 70 years), comorbid diseases such as diabetes, hypertension, and rheumatoid arthritis (RA) were independent risk factors for the development of ONJ. In addition, tooth extraction (HR 9.85), gingivitis, and periodontal disease (HR 4.78) were strongly associated with ONJ. Conclusions: ONJ incidence was 21 per 100,000 person-years in osteoporosis patients receiving bisphosphonates. Clinical factors including advanced age, diabetes, RA, dental disease, as well as BP use were significantly associated with ONJ.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] No increased risk of osteonecrosis of the jaw in osteoporotic patients with dental implants: a nationwide cohort study
    Jung-Hyun Park
    Jae-Ryun Lee
    Hyejin Lee
    Hyo-Jung Lee
    Jin-Woo Kim
    Clinical Oral Investigations, 28
  • [22] Use of oral bisphosphonates and risk of hospital admission with osteonecrosis of the jaw: Large prospective cohort study in UK women
    Wotton, Clare J.
    Green, Jane
    Brown, Anna
    Armstrong, Miranda E. G.
    Floud, Sarah
    Beral, Valerie
    Reeves, Gillian K.
    Abbiss, Hayley
    Abbott, Simon
    Alison, Rupert
    Armstrong, Miranda
    Baker, Krys
    Balkwill, Angela
    Barnes, Isobel
    Beral, Valerie
    Black, Judith
    Blanks, Roger
    Bradbury, Kathryn
    Brown, Anna
    Cairns, Benjamin
    Canoy, Dexter
    Chadwick, Andrew
    Ewart, Dave
    Ewart, Sarah
    Fletcher, Lee
    Floud, Sarah
    Gathani, Toral
    Gerrard, Laura
    Goodill, Adrian
    Green, Jane
    Guiver, Lynden
    Heath, Alicia
    Hermon, Carol
    Hogg, Darren
    Hozak, Michal
    Lingard, Isobel
    Kan, Sau Wan
    Langston, Nicky
    Moser, Kath
    Pitie, Kirstin
    Price, Alison
    Reeves, Gillian
    Shaw, Keith
    Sherman, Emma
    Simpson, Rachel
    Strange, Helena
    Sweetland, Sian
    Tipper, Sarah
    Travis, Ruth
    Trickett, Lyndsey
    BONE, 2019, 124 : 69 - 74
  • [23] Incidence and severity of medication-related osteonecrosis of the jaw in patients with osteoporosis using data from a Korean nationwide sample cohort in 2002 to 2019: a retrospective study
    Ko, Su-Youn
    Hwang, Tae-Yoon
    Baek, Kiwook
    Park, Chulyong
    JOURNAL OF YEUNGNAM MEDICAL SCIENCE, 2024, 41 (01): : 39 - 44
  • [24] Osteonecrosis of the jaw and survival of patients with cancer: a nationwide cohort study in Denmark
    Corraini, Priscila
    Heide-Jorgensen, Uffe
    Schiodt, Morten
    Norholt, Sven Erik
    Acquavella, John
    Sorensen, Henrik Toft
    Ehrenstein, Vera
    CANCER MEDICINE, 2017, 6 (10): : 2271 - 2277
  • [25] Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: Not just a sporadic coincidence - a multi-centre study
    Otto, Sven
    Abu-Id, Mario Hakim
    Fedele, Stefano
    Warnke, Patrick H.
    Becker, Stephan T.
    Kolk, Andreas
    Muecke, Thomas
    Mast, Gerson
    Koehnke, Robert
    Volkmer, Elias
    Haasters, Florian
    Lieger, Olivier
    Iizuka, Tateyuki
    Porter, Stephen
    Campisi, Giuseppina
    Colella, Giuseppe
    Ploder, Oliver
    Neff, Andreas
    Wiltfang, Joerg
    Ehrenfeld, Michael
    Kreusch, Thomas
    Wolff, Klaus-Dietrich
    Stuerzenbaum, Stephen R.
    Schieker, Matthias
    Pautke, Christoph
    JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY, 2011, 39 (04) : 272 - 277
  • [26] Is implant surgery a risk factor for osteonecrosis of the jaw in older adult patients with osteoporosis? A national cohort propensity score-matched study
    Ryu, Jae-In
    Kim, Ha-Young
    Kwon, Yong-Dae
    CLINICAL ORAL IMPLANTS RESEARCH, 2021, 32 (04) : 437 - 447
  • [27] Jaw osteonecrosis in patients treated with bisphosphonates: MDCT evaluation
    Milillo, P.
    Garribba, A. P.
    Favia, G.
    Ettorre, G. C.
    RADIOLOGIA MEDICA, 2007, 112 (04): : 603 - 611
  • [28] Jaw osteonecrosis in patients treated with bisphosphonates: MDCT evaluation
    Milillo P.
    Garribba A.P.
    Favia G.
    Ettorre G.C.
    La radiologia medica, 2007, 112 (4) : 603 - 611
  • [29] Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan
    Fang-Chun Liu
    Kwing-Chi Luk
    Yung-Chih Chen
    Osteoporosis International, 2023, 34 : 1729 - 1737
  • [30] The increase in prescriptions of bisphosphonates and the incidence proportion of osteonecrosis of the jaw after risk communication activities in Japan: a hospital - based cohort study
    Sumi, Eriko
    Yamazaki, Toru
    Tanaka, Shiro
    Yamamoto, Keiichi
    Nakayama, Takeo
    Bessho, Kazuhisa
    Yokode, Masayuki
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 (04) : 398 - 405